• KOL
    • KOLs Community
    • Vernal
    • Vernal Keratoconjunctivitis
    • Andrea A Leonardi
    • Andrea A Leonardi

      Andrea A Leonardi

      Department of Neuroscience, Ophthalmology Unit, University of Padova, Italy. Electronic address: andrea.leonardi@unipd.it. | Department of Neurosciences, Ophthalmology Unit, ...

       

       

      KOL Resume for Andrea A Leonardi

      Year
      2022

      Department of Neuroscience, Ophthalmology Unit, University of Padova, Italy. Electronic address:

      2021

      Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua.

      University of Padova

      2020

      Department of Neuroscience, Ophthalmology Unit, University of Padova , Padova, Italy.

      2019

      Ophthalmology Unit, Department of Neuroscience, University of Padua, Padua, Italy

      2018

      Department of Neuroscience, Ophthalmology Unit, University of Padova, Padova, Italy,

      2017

      Department of Neurosciences, Ophthalmology Unit, University of Padua, Padua,

      2016

      Ophthalmology Unit Department of Neuroscience University of Padua Padua Italy

      2015

      University of Padua Department of Neuroscience Ophthalmology Unit Padua Italy

      2013

      Ophthalmology Unit, Department of Neuroscience, University of Padua, Padua

      2012

      Department of Neuroscience, University of Padua, Padua, Italy

      2011

      Department of Ophthalmology, University of Padua, Padua, Italy

      2010

      Department of Neuroscience, Ophthalmology Unit, University of Padua, Via Giustiniani 2, 35128 Padova, Italy. Department of Neuroscience, Ophthalmology Unit, University of Padua, Via Giustiniani 2, 35128 Padova, Italy.

      Ophthalmology Unit, University of Padua, 2, I-35128, Via Giustiniani, Padua, Italy

      2009

      Department of Neuroscience, Ophthalmology Unit, University of Padova, Italy

      2008

      Ophthalmology Unit, Department of Neuroscience, University of Padua, Italy

      2007

      Ophthalmology Unit, Department of Neuroscience, University of Padua, Italy,

      2006

      Department of Neuroscience, Ophthalmology Unit, University of Padova, Padova, Italy (Drs Motterle and Leonardi)

      2005

      Department of Neuroscience, Ophthalmology Unit, University of Padua, Padua, Italy.

      2004

      Ophthalmology Unit, University of Padova, Padova,

      2003

      Department of Laboratory Medicine; and the

      Ophthalmology Unit, University of Padova, Padova, Italy

      2002

      From the Departments of Ophthalmology (A.L., A.G.S.) and Laboratory Medicine (A.L.), University of Padova, Italy; and the Medical Division of SIFI S.p.A. (V.P., G.M.), Catania, Italy.

      Department of Ophthalmology and Allergy Service Department of Laboratory Medicine, University of Padua,Via Giustiniani 2, 35128 Padova, Italy

      2001

      Department of Ophthalmology, University of Padua, Padua, Italy (Drs Secchi and Leonardi)

      2000

      Ophthalmology and Ocular Inflammation Unit, Department of Neuroscience, University of Padova, Italy.

      Department of Laboratory Medicine (Drs Leonardi, Borghesan, Faggian, DePaoli, and Plebani), Hospital and University of Padova, Padua, Italy

      1999

      Department of Clinical Ophthalmology, University of Padua Medical School, Padua, Italy

      1998

      Institute of Physiopathological Optics, University of Padova, Italy

      1997

      Department of Physiopathological Optics, University of Padua, Italy.

      1996

      Institute of Ophthalmology, Department of Physiopathological Optics, University of Padova - Padova

      1995

      Institute of Ophthalmology, University of Padova, Italy.

      1993

      Department of Ophthalmology, Chair of Physiological Optics, University of Padua, Italy

      1992

      Istituto di Clinica Oculistica, Càttedra di Ottica Fisiopatològica, University of Padova, Italy;, Eye Research Institute and Department of Ophthalmology, Harvard Medical School, Boston, Mass., USA

      1991

      Immunology Unit, Eye Research Institute, Boston, Mass., USA;, Department of Ophthalmology, Chair of Physiopathological Optic, University of Padova, Italy

      1990

      Institute of Ophthalmology, University of Padova School of Medicine, Padova, Italy

       

       

      Andrea A Leonardi: Influence Statistics

      Sample of concepts for which Andrea A Leonardi is among the top experts in the world.
      Concept World rank
      ideal frequent site #1
      naaga reduction #1
      005 tolerability #1
      pathophysiology allergic conjunctivitis #1
      1 eye ketotifen #1
      conjunctivitis ketotifen #1
      nonatopic vkc patients #1
      olopatadine reduced #1
      vkc corneal complications #1
      placebo ketotifen #1
      h1 vernal tissues #1
      emedastine eye #1
      emedastine ketotifen #1
      levo reduction #1
      2 agents placebo #1
      ocular inflammation summary #1
      histamine tear levels #1
      3003 ophthalmologists #1
      review immunopathogenesis #1
      cultured child conjunctivitis #1
      ivcm corneal microstructural #1
      th1 vkc #1
      ecp tear levels #1
      005 ophthalmic solution #1
      versus levocabastine #1
      active allergic patients #1
      small tear samples #1
      vkcclek epithelial damage #1
      netilmicin ofloxacin #1
      vkc vkcclek #1
      patients vkc #1
      identification inflammatory mediators #1
      allergic cytokines #1
      hypotheses disease duration #1
      conjunctival fibroblast cultures #1
      derived vkc #1
      ocular antiallergic compounds #1
      massive eosinophil attraction #1
      severe visual complications #1
      life illness staining #1
      pathogenesis vkc #1

       

      Prominent publications by Andrea A Leonardi

      KOL-Index: 15133

      OBJECTIVE: The purpose of this study was to assess the effects of olopatadine on the release of mast cell-derived mediators after conjunctival allergen challenge(CAC) in humans.

      METHODS: This was a double-masked, randomized, placebo-controlled clinical trial. Subjects with a clinical history of seasonal allergic conjunctivitis (but no current symptoms or treatment at baseline) were studied. At visit 1, subjects underwent bilateral CAC with increasing doses of allergen every 15 minutes ...

      Known for Mast Cell | Olopatadine Placebo | Visit Subjects | Conjunctival Allergen | Itching Redness
      KOL-Index: 14623

      BACKGROUND: Emedastine difumarate 0.05% ophthalmic solution and ketotifen fumarate 0.025% ophthalmic solution are 2 topical antiallergic agents available in the United States and other countries. Emedastine is indicated for the temporary relief of the signs and symptoms of allergic conjunctivitis. Ketotifen is indicated for the temporary relief of ocular itching caused by allergic conjunctivitis.

      OBJECTIVE: The purpose of this study was to compare the efficacy of these agents in the ...

      Known for Ophthalmic Solution | Allergic Conjunctivitis | Emedastine Ketotifen | Cac Model | Allergen Challenge
      KOL-Index: 13283

      PURPOSE: The SANSIKA study was conducted to assess the treatment effect of 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops on signs and symptoms of patients with severe dry eye disease (DED).

      METHODS: This was a multicenter, randomized, double-masked, 2-parallel-arm, 6-month phase III study with a 6-month open-label treatment safety follow-up. Patients with severe DED with corneal fluorescein staining (CFS) grade 4 on the modified Oxford scale were randomized to receive ...

      Known for Cationic Emulsion | Csa Vehicle | Severe Dry | Eye Disease | Baseline Month
      KOL-Index: 12236

      PURPOSE: The SICCANOVE study aimed to compare the efficacy and safety of 0.1% cyclosporine A cationic emulsion (CsA CE) versus vehicle in patients with moderate to severe dry eye disease (DED).

      METHODS: In this multicenter, double-masked, parallel-group, controlled study, patients were randomized (1:1) to receive CsA CE (Ikervis®) or vehicle for 6 months. The co-primary efficacy endpoints at month 6 were mean change from baseline in corneal fluorescein staining (CFS; modified Oxford ...

      Known for Patients Csa | Dry Eye | 6 Months | Efficacy Safety | Baseline Month
      KOL-Index: 11752

      PURPOSE: To study levels and activity of matrix metalloproteinase (MMP)-1 and -9 and their tissue inhibitor (TIMP-1) in tears of patients with vernal keratoconjunctivitis (VKC), with and without severe corneal damage.

      METHODS: Tear samples were obtained from 16 patients with active VKC and 10 normal control subjects, after clinical evaluation and tear cytology. Tear levels of pro-MMP-1, pro-MMP-9, and TIMP-1 were measured by enzyme-linked immunosorbent assay (ELISA). Collagenase and ...

      Known for Matrix Metalloproteinase | Vernal Keratoconjunctivitis | Tear Levels | Vkc Mmp1 | Mmp9 Activity
      KOL-Index: 11685

      OBJECTIVE: Eotaxin-1 and eotaxin-2 are potent eosinophil chemotactic and activating peptides that may be implicated in the pathogenesis of the chronic allergic eye diseases vernal keratoconjunctivitis (VKC) and atopic keratoconjunctivitis (AKC). The purpose of this study was to measure these chemokines in tear and mucus samples of active-disease patients and in vitro cultured conjunctival epithelial cells and fibroblasts.

      DESIGN: Comparative, observational case series and in vitro ...

      Known for Vkc Patients | Chemotactic Factors | Chemokines Tears | Eotaxin1 Eotaxin2 | Conjunctival Fibroblasts
      KOL-Index: 11522

      BACKGROUND: Several cytokines are involved in the recruitment and activation of inflammatory cells in ocular allergic diseases. The purpose of the study was to assay multiple cytokines and chemokines in tears, to compare subgroups of allergic conjunctivitis (AC) with controls, and in culture supernatants to determine whether conjunctival fibroblasts produce some of these cytokines.

      METHODS: Fifty to one hundred microlitre tears were obtained from patients with active seasonal allergic ...

      Known for Chemokines Tears | Allergic Cytokines | Sac Vkc | Tnf Alpha | Eye Disease
      KOL-Index: 10799

      PURPOSE: Conjunctival fibroblasts stimulated with histamine (H) may be directly involved in the inflammatory and remodeling processes of chronic allergic conjunctival diseases.

      METHODS: Proinflammatory cytokine and growth factor production, and the expression of intercellular adhesion molecule-1 (ICAM-1) were studied in conjunctival fibroblast cultures challenged with different concentrations of H (from 10(-9) M to 10(-) (4) M). Interleukin (IL)-1, IL-4, IL-6, IL-8, tumor necrosis ...

      Known for Conjunctival Fibroblasts | Icam1 Expression | Intercellular Adhesion | Histamine Production | H1 Antagonists
      KOL-Index: 10745

      BACKGROUND: To detect the presence of multiple mediators and growth factors in tears of vernal keratoconjunctivitis (VKC) patients with active disease using stationary phase antibody arrays.

      METHODS: Tears were collected from 12 normal subjects (CT) and 24 active VKC patients. Tears were centrifuged and successively probed using three microwell plate arrays specific for: (i) cytokines: interleukin (IL)-2, IL-4, IL-5, IL-8, IL-10, IL-12, IL-13, interferon-gamma and tumour necrosis ...

      Known for Growth Factor | Allergic Cytokines | Vkc Patients | Normal Subjects | Vernal Keratoconjunctivitis
      KOL-Index: 10698

      To quantify the presence of inflammatory/fibrogenic cytokines and procollagens type I (PICP) and III (PIIIP) in active and non-active tarsal and limbal forms of vernal keratoconjunctivitis (VKC), tear and blood samples were collected from 27 VKC patients (20 active and 7 non-active) and 15 normal subjects. Upper tarsal conjunctival biopses were obtained from 8 controls and 8 tarsal VKC patients. From biopses of 4 tarsal VKC, fibroblasts were cultured in F12 medium with 10% FCS. TGF-beta ...

      Known for Vernal Keratoconjunctivitis | Vkc Patients | Conjunctiva Conjunctivitis | Limbal Forms | Tnf Alpha
      KOL-Index: 10685

      PURPOSE: The SANSIKA study evaluated the efficacy/safety of 0.1% (1 mg/mL) cyclosporine A cationic emulsion (CsA CE) for treating dry eye disease (DED) with severe keratitis. The double-masked phase demonstrated that CsA CE was effective in reducing corneal damage and ocular surface inflammation, and was well-tolerated over 6 months. Here we report efficacy and safety findings of SANSIKA's open-label extension (OLE).

      METHODS: In this multicenter, double-masked, phase III study, patients ...

      Known for Cationic Emulsion | Dry Eye | Severe Keratitis | 6 Months | Corneal Fluorescein
      KOL-Index: 10218

      PURPOSE: To determine whether cytokines involved in chronic allergic conjunctival disorders may affect formation of giant papillae and tissue remodeling.

      METHODS: Conjunctival fibroblast cultures were challenged with different concentrations of human recombinant interleukin (IL)-4, IL-13, interferon (IFN)-gamma and tumor necrosis factor (TNF)-alpha. Procollagens I (PIP) and III (PIIIP), matrix metalloproteinase (MMP)-1 and -9, and tissue inhibitor of metalloproteinase (TIMP)-1 were ...

      Known for Conjunctival Fibroblasts | Th2 Cytokines | Expression Mmp1 | Matrix Metalloproteinase | Tissue Inhibitor
      KOL-Index: 10142

      PURPOSE: Plasminogen activators play a role, not only in fibrinolysis but also in events such as chemotaxis, collagen degradation, and cell spreading. The serine protease urokinase (uPA) is a potent chemoattractant for leukocytes that may be involved in the pathogenesis of severe forms of allergic conjunctivitis such as vernal keratoconjunctivitis (VKC).

      METHODS: Tear and peripheral blood samples were obtained from 20 patients with active VKC and from 19 normal subjects who formed the ...

      Known for Plasminogen Activator | Upa Upar | Vernal Keratoconjunctivitis | Patients Vkc | Increased Expression
      KOL-Index: 9855

      Histamine, an important mast cell mediator in allergic disorders, may affect extracellular matrix production and cell growth in vernal keratoconjunctivitis (VKC). In the present study, the histamine reactivity of conjunctival fibroblasts derived from VKC patients was investigated in vitro. Conjunctival fibroblast cultures were derived from biopses of 8 tarsal VKC patients and 5 normal subjects. These cells were maintained in vitro and stimulated with different concentrations of histamine ...

      Known for Conjunctival Fibroblasts | Histamine Effects | Vkc Patients | Vernal Conjunctivitis | Cell Migration

      Key People For Vernal Keratoconjunctivitis

      Top KOLs in the world
      #1
      Andrea A Leonardi
      vernal keratoconjunctivitis allergic conjunctivitis ocular allergy
      #2
      Stefano Bonini
      ocular surface nerve growth factor vernal keratoconjunctivitis
      #3
      Alessandro Lambiase
      nerve growth factor vernal keratoconjunctivitis ocular surface
      #4
      Sergio Bonini
      allergic rhinitis nerve growth factor vernal keratoconjunctivitis
      #5
      Antonio Giovanni Secchi
      islet transplantation type 1 diabetic patients
      #6
      Laura Magrini
      emergency department planetary nebulae gaiaeso survey

      Andrea A Leonardi:Expert Impact

      Concepts for whichAndrea A Leonardihas direct influence:Vernal keratoconjunctivitis,  Allergic conjunctivitis,  Ocular allergy,  Vkc patients,  Cationic emulsion,  Patients vkc,  Ocular surface,  Growth factors.

      Andrea A Leonardi:KOL impact

      Concepts related to the work of other authors for whichfor which Andrea A Leonardi has influence:Allergic conjunctivitis,  Ocular allergy,  Dry eye,  Mast cells,  Topical cyclosporine,  Diabetic retinopathy,  Tear fluid.


       

      Tools

      Is this your profile? manage_accounts Claim your profile content_copy Copy URL code Embed Link to your profile


      Department of Neuroscience, Ophthalmology Unit, University of Padova, Italy. Electronic address: andrea.leonardi@unipd.it. | Department of Neurosciences, Ophthalmology Unit, University of Padua, Padua, Italy. | Department of Neuroscience, Ophthalmolo

    Download on the App StoreGet it on Google Play

    Copyright © 2023 - KOL means Key Opinion Leaders .

    KOL does not provide medical advice, diagnosis or treatment.